A Florida-based biopharmaceutical company is giving hope to patients with rare debilitating diseases by developing innovative therapies designed specifically to improve and alleviate their symptoms. The main focus of Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) is the development of a treatment for Lambert-Eaton Myasthenic Syndrome (LEMS) – a rare, autoimmune, neuromuscular disorder characterized by muscle weakness and autonomic dysfunction.
With a prevalence of approximately 1 in 100,000 people in the United States and Canada, this ailment can be severely debilitating, as its primary symptoms are severe muscle weakness and fatigue. The disease occurs when the immune system starts attacking the nerves that control muscles, more specifically nerve cell proteins that regulate how much acetylcholine, a neurotransmitter, is released. When the body cannot release enough of it, regular muscle contractions that allow walking, wiggling one’s fingers or shrugging one’s shoulders become…
NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW is uniquely positioned to best serve private and public companies who need to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, visit https://www.NetworkNewsWire.com
Please see full disclaimers on the NetworkNewsWire website: http://nnw.fm/Disclaimer